Crohn’s disease treatment

Calcium-channel blockers for the treatment of hypertension Calcium products Cephalosporins Cerebroactive medications Chlamydial infections treatment of Cholinergic drugs uses in medicine Cholinergic-receptor-blocking agents uses of Cirrhosis treatment of Congestive heart failure treatment of Constipation drug-induced Corticosteroids uses for Crohn s disease treatment of Cytokines their actions... 

OA were aborted in 2003 due to the development of mild to moderate liver fibrosis in dogs treated for 9 months with high doses of pralnacasan. This was in spite of recent evidence demonstrating the effectiveness of pralnacasan treatment in the acute dextran sulfate sodium (DSS)-induced colitis model, which resembles Crohn s disease (CD) characteristics, and in transient ischemia induced brain damage. 

Crohn s disease, rheumatoid arthritis Treatment of active to moderate ulcerative colitis, proctosigmoiditis, or proctitis... 

Bismudi subsalicylate is used in combination witii otiier dru > to treat gastric and duodenal ulcers caused by H. pylori bacteria Mesalamine is used in the treatment of chronic inflammatoiy bowel disease Misoprostol is used to prevent gastric ulcers in those taking aspirin or nonsteroidal anti-inflammatory dragp in high doses for a prolonged time Olsalazine is used in the treatment of ulcerative colitis in those allergic to sulfasalazine. Sulfasalazine is used in the treatment of Crohn s disease and ulcerative colitis. Sucralfate is used in the treatment of duodenal ulcer. 

Use treatment of gastrointestinal disorders (ulcerative colitis, Crohn s disease)... 

Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn s disease. Free Rad. Biol. Med. 7, 145-149. 

The inhibition of the phosphorylation of IkBoc by celastrol in the NF-kB signaling pathway is not cell specific72-75 and thus significantly broadened the potential medicinal applications of natural triterpene QMs. Celastrol 76 has been evaluated in the treatment of Crohn s disease,76 which is a chronic relapsing inflammatory bowel disease. In the peripheral blood mononuclear cells, celastrol 76 reduced the levels of... 

Describe pharmacologic treatment options for patients with acute or chronic symptoms of ulcerative colitis and Crohn s disease. 

Create a patient-specific drug treatment plan based on symptoms, severity, and location of ulcerative colitis or Crohn s disease. 

Treatment of active mild to moderate Crohn s disease involves use of oral or topical aminosalicylate derivatives, whereas moderate to severe disease may require systemic corticosteroid therapy. 

Sandborn WJ. Evidence based treatment algorithm for mild to moderate Crohn s disease. Am J Gastroenterol 2003 98( 12 Suppl) Sl-S5. 

Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine dmgs, such as 6-mercaptopurine (6-MP), 6-thioguanine and azathioprine, to inactive metabolites [29-32]. Thiopurines form part of the routine treatment for patients with acute lymphoblastic leukemia, rheumatoid arthritis, and autoimmune diseases such as SLE and Crohn s disease, and are used as an immunosuppressant following organ transplantation. 

Castiglione F, Rispo A, Di Girolamo E, Cozzo-lino A, Manguso F, Grassia R, et al Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn s disease. Aliment Pharmacol Ther 2003,18 1107-1112. 

An increasing number of both clinical and laboratory-derived observations support the importance of luminal components in driving the inflammatory response in ulcerative colitis and Crohn s disease. Although its role is unclear, antibiotic therapy is commonly used in clinical practice for the treatment of moderately to severely active ulcerative colitis. Metronidazole and/or ciprofloxacin are currently employed in active Crohn s disease, particularly in patients with colonic involvement and with perianal disease. Rifaximin, a rifamycin-derived antibiotic, is characterized by a wide range of antibacterial activity and a very low systemic absorption. Some preliminary data show its efficacy in severe active ulcerative colitis, pouchitis and prevention of postoperative recurrence in Crohn s disease. 

Finally, Shafran et al. [52] presented recently an open-label study on the efficacy and safety of rifaximin 600 mg/ day for 16 weeks in the treatment of mildly to moderately active CD. At the end of the study, 59% of patients were in remission (as defined by a Crohn s Disease Activity Index, CDAI, <150) with a significant reduction of the... 

Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Lennard-Jones JE Antibiotic therapy for treatment in relapse of intestinal Crohn s disease. A prospective randomized study. Dis Colon Rectum 1985 28 81-85. 

Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzzi C An antibiotic regimen for the treatment of active Crohn s disease A randomized controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996,91 328-332. 

Colombel JF, Lemann M, Cassagnou M, Bouh-nik Y, Duclols B, Dupas JL, Notteghem B, Mary JY A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn s disease. Am J Gastroenterol 1999 94 674-678. 

---